Formulation and evaluation of ranolazine extended release tablets: Influence of polymers

Murthy TEGK, Bala Vishnu Priya Mukkala, Suresh Babu VV

Abstract


An extended release tablet provides prolonged periods of drug in plasma levels thereby reduce dosing frequency,improve patient compliance and reduce the dose-related side effects. Ranolazine is indicated for the chronic treatment
of angina in patients who have not achieved an adequate response with other anti-anginal agents. The present investigationwas undertaken to design extended release tablets of Ranolazine employing hypromellose phthalate grade HP-55, ethocel standard 7FP premium ethyl cellulose, Surelease E-7-19040, Klucel HF pharm and Natrosol Type 250 HHX as matrix forming agents using wet granulation method. Formulated tablets were evaluated for uniformity of weight, assay, water content, in vitro drug release studies and stability studies.The drug release followed first order kinetics with both erosion and diffusion as the release mechanism. It is concluded that the desired drug release pattern can be obtained by using natrosol type 250 HHX compared to other polymers. The similarity factor (f2) was calculated to select best formulation by comparing in vitro dissolution data of the commercial formulation Ranexa®. The formulated tablets fulfilled the compendia requirements. The formulated Ranolazine Extended release tablets were found to be stable.


Full Text:

PDF

References


Remington. The science and practice of pharmacy. 21st ed. USA:

Lippincott, Williams and Wilkins Publications; 2005. p. 939-64.

Thomson. Physician Desk Reference. 61st ed. Montvale, New Jersey:

Thomson PDR; 2007, p. 1035-37.

Ferrero Rodriguez C, Bruneau N, Barra J, Alfonso D, Doelker E.

Hydrophilic Cellulose derivatives as drug delivery carriers: influence

of substitution type on the properties of compressed matrix tablets,

In: Wise DL, editor Handbook of Pharmaceutical Controlled Release

Technology. New York: Marcel Dekker; 2000. p. 1-30.

Lee PI, Diffusional release of a solute from polymeric matrix-

approximate analytical solutions. Journal of Membrane Science

:7:255-75.

Tiwari S, Rajabi-Siahboomi AR, Extended-release oral drug delivery

technologies: monolithic matrix systems. Drug delivery systems.

Totowa NJ, Jain KK, editors. New York: Humana Press; 2008. p. 217-43.

Vass S, Deng H, Rajabi-Siahboomi AR, Investigation of ethylcellulose in

the preparation of theophylline extended release inert matrix tablets,

AAPS annual meeting and exposition; 2008.

Ruiz NR, Ghaly ES. Mechanism of drug release from matrices prepared

with aqueous dispersion of ethylcellulose. Drug Dev Ind Pharm

:23:113-7.

The United States Pharmacopeia, 34th revision and the National

formulary. 29th ed., vol. 1. The United States Pharmacopeial Convention,

Twinbrook Parkway, MD 20852; 2011. p. 403-6.

The United States Pharmacopeia, 34th revision and the National

formulary. 29th ed., vol. 1. The United States Pharmacopeial Convention,

Twinbrook Parkway, MD 20852; 2011. p. 407-10.

Available from: http://www.accessdatadata.fda.gov/scripts/cder/

dissolution/dsp_searchresults_dissolution. Cfm. [Last accessed on

Jul 19].

A v a i l a b l e f r o m : h t t p : / / w w w. f d a . g o v / d o w n l o a d s / d r u g s /

guidancecomplianceregulatoryinformation/guidances/ ucm201217.

pdf. [Last accessed on 2011 Jul 19].

Kulkarni SV, Kumar PR, Rao BS, Kumar PA, Ramesh B, Pranitha Y,

et al. Preparation and in vitro evaluation of controlled release matrix

tablets of stavudine using natural and synthetic polymers. J Pharm Res

:3:1463-66.




DOI: http://dx.doi.org/10.22377/ajp.v5i3.102

Refbacks

  • There are currently no refbacks.